Telomir Pharmaceuticals, Inc. - Form 8-K Filing

On December 15, 2025, Telomir Pharmaceuticals, Inc. (the "Company") announced that its Compensation Committee and Board of Directors approved several incentive actions for its CEO, Erez Aminov. These include a short-term incentive payout of $400,000 for 2025 performance, a potential $150,000 milestone payout upon FDA acceptance of an IND submission for Telomir-1, and a transaction advisory award of 3% of the total TELI transaction value for Mr. Aminov's leadership in the potential acquisition of TELI Pharmaceuticals, Inc. The award can be paid in cash or equity and will vest immediately upon closing. Additionally, Mr. Aminov's base salary will be adjusted to $500,000, effective January 1, 2026. The Company will prepare the necessary documentation and SEC filings related to these actions. The filing also notes that the company is an emerging growth company and that its common stock is traded on The Nasdaq Stock Market LLC under the symbol TELO.